Trials / Completed
CompletedNCT03735030
Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation
Comparative Bioavailability Study of Choriomon® (IBSA) Versus a Marketed hCG Formulation, Following Subcutaneous Administration in Healthy Women. Single-dose, Open-label, Randomized, Two-period, Two-way Cross-over, Bioavailability Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- IBSA Institut Biochimique SA · Industry
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
In the present study, the rate and extent of hCG absorption will be compared between the two treatments in healthy women aged 20 to 45 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human hCG 10'000 IU | A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers. |
| DRUG | Recombinant hCG 6'500 IU | A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers. |
Timeline
- Start date
- 2018-11-27
- Primary completion
- 2019-08-02
- Completion
- 2019-08-02
- First posted
- 2018-11-08
- Last updated
- 2021-03-11
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03735030. Inclusion in this directory is not an endorsement.